BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Efentakis P, Doerschmann H, Witzler C, Siemer S, Nikolaou PE, Kastritis E, Stauber R, Dimopoulos MA, Wenzel P, Andreadou I, Terpos E. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. Int J Mol Sci 2020;21:E5185. [PMID: 32707866 DOI: 10.3390/ijms21155185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Schlesser C, Meul T, Stathopoulos G, Meiners S. Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib. Biomolecules 2022;12:756. [DOI: 10.3390/biom12060756] [Reference Citation Analysis]
2 Efentakis P, Psarakou G, Varela A, Papanagnou ED, Chatzistefanou M, Nikolaou PE, Davos CH, Gavriatopoulou M, Trougakos IP, Dimopoulos MA, Andreadou I, Terpos E. Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. Int J Mol Sci 2021;22:10956. [PMID: 34681615 DOI: 10.3390/ijms222010956] [Reference Citation Analysis]
3 Terpos E, Stamatelopoulos K, Makris N, Georgiopoulos G, Ntanasis-Stathopoulos I, Gavriatopoulou M, Laina A, Eleutherakis-Papaiakovou E, Fotiou D, Kanellias N, Malandrakis P, Delialis D, Andreadou I, Kastritis E, Dimopoulos MA. Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers (Basel) 2021;13:5057. [PMID: 34680206 DOI: 10.3390/cancers13205057] [Reference Citation Analysis]
4 Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Circ Res 2021;128:1576-93. [PMID: 33983833 DOI: 10.1161/CIRCRESAHA.121.318223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]